Diana Barb

Diana Barb

Auto-generated profile, based on publicly available information

Diana Barb

Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida at Gainesville , FL 32610

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2023 in Hepatology
Verified
Journal Article
Closed access
MRMary E. Rinella
Mary E. Rinella
BNBrent A. Neuschwander-Tetri
Brent A. Neuschwander-Tetri
MSMohammad Shadab Siddiqui
Mohammad Shadab Siddiqui
MAManal F Abdelmalek
Manal F Abdelmalek
SCStephen Caldwell
Stephen Caldwell
RLRohit Loomba
Rohit Loomba

1 November 2015 in Ageing Research Reviews
Verified
Journal Article
Closed access
Stephen AntonStephen Anton
Stephen Anton
AWAdam J. Woods
Adam J. Woods
TATetso Ashizawa
Tetso Ashizawa
DBDiana Barb
Diana Barb
TBThomas Buford
Thomas Buford
MPMarco Pahor
Marco Pahor

5 July 2021 in Liver International
Verified
Journal Article
Open access
PDF file
Amalia GastaldelliAmalia Gastaldelli
Amalia Gastaldelli
SSSilvia Sabatini
Silvia Sabatini
FCFabrizia Carli
Fabrizia Carli
Melania GagginiMelania Gaggini
Melania Gaggini
FBFernando Bril
Fernando Bril
KCKenneth Cusi
Kenneth Cusi
Background and Aims: Peroxisome proliferator‐activated receptor (PPAR)‐γ agonists decrease hepatic/visceral fat (VF) and improve necroinflammation despite subcutaneous (SC) fat weight‐gain. Understanding the impact of changes in VF, VF‐to‐SC fat distribution (VF/SC) and adiponectin (ADPN) levels in relation to histological improvement after weight‐loss or pioglitazone is relevant as novel PPAR‐γ agonists are being developed for treating non‐alcoholic steatohepatitis (NASH).Methods: Fifty‐five patients with NASH received a −500 kcal/d hypocaloric diet and were randomized (double‐blind) to pioglitazone (45 mg/d) or placebo for 6‐months. Before and after treatment patients underwent a liver biopsy and measurement of hepatic/peripheral glucose fluxes, hepatic/adipose tissue‐IR and, in 35 patients, hepatic and VF/SC‐fat was measured by magnetic resonance spectroscopy/imaging. Data were examined by multivariable statistical analyses combined with machine‐learning techniques (partial least square discriminant analysis [PLS‐DA]).Results: Both pioglitazone (despite weight‐gain) and placebo (if weight‐loss) reduced steatosis but only pioglitazone ameliorated necroinflammation. Using machine‐learning PLS‐DA showed that the treatment differences induced by a PPAR‐γ agonist vs placebo on metabolic variables and liver histology could be best explained by the increase in ADPN and a decrease in VF/SC, and to a lesser degree, improvement in oral glucose tolerance test‐glucose concentrations and ALT. Decrease in steatosis and disease activity score (ballooning plus lobular inflammation) kept a close relationship with an increase in ADPN (r = −.71 and r = −.44, P < .007, respectively) and reduction in VF/SC fat (r = .41 and r = .37, P < .03 respectively).Conclusions: Reduction in VF and improved VF/SC‐distribution, combined with an increase in ADPN, mediate the histological benefits of PPAR‐γ action, highlighting the central role of fat metabolism and its distribution on steatohepatitis disease activity in patients with NASH.

15 February 2024 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
LALayla A. Abushamat
Layla A. Abushamat
PSPir Ahmad Shah
Pir Ahmad Shah
RERobert H. Eckel
Robert H. Eckel
SHStephen A. Harrison
Stephen A. Harrison
DBDiana Barb
Diana Barb
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects one in three to four adult individuals and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Insulin resistance plays a central role in MASLD/MASH pathophysiology with higher rates of MASLD (two in three) and MASH with fibrosis (one in five) in adults with obesity and diabetes. This review summarizes the role of glucagon-like peptide (GLP) -1 receptor agonists in treating MASLD/MASH. Although not approved by the Food and Drug Administration for the treatment of MASLD, this class of medication is available to treat obesity and type 2 diabetes and has been shown to reverse steatohepatitis, reduce cardiovascular risk, and is safe to use across the spectrum of MASLD with or without fibrosis.

9 September 2020 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
NFNada Fanous
Nada Fanous
DBDiana Barb
Diana Barb
A 49-year-old woman, previously healthy, presented with recurrent fractures provoked by minimal trauma. She had sustained seven fractures over the previous 2 years. While she was an avid runner, her injuries were determined to be out of proportion to the degree of trauma. Initial evaluation, exploring the more common causes such as low bone density and abnormal vitamin D metabolism, was unremarkable. On repeat of the some of the tests, a low alkaline phosphatase (AP) was noted, which raised suspicion for hypophosphatasia (HPP), a rare cause of recurrent fractures. Subsequent workup revealed a low bone-specific AP and elevated vitamin B6. Subsequently, genetic testing confirmed the diagnosis of adult-onset HPP caused by a heterozygous mutation c.407G>A in the ALPL gene. Asfotase alfa was started; however, the patient developed an allergic reaction leading to the discontinuation of the drug.

11 February 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ARAndrea Ortiz Rocha
Andrea Ortiz Rocha
SKSrilaxmi Kalavalapalli
Srilaxmi Kalavalapalli
ELEddison Godinez Leiva
Eddison Godinez Leiva
DBDiana Barb
Diana Barb
FBFernando Bril
Fernando Bril
KCKenneth Cusi
Kenneth Cusi
Context Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). Objective In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear. Methods We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild–moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE). Results Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001). Conclusion In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.